Abstract

BackgroundOver the last years, the differentiation and activation of MDSC under tumor conditions has been studied extensively. Various tumor-derived factors have been identified in promoting the accumulation of this suppressive...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
New Mechanism in Anti Tumor Activity of Poly (I:C): Modulation of Tumor-Associated Myeloid Derived Suppressor Cells in Murine Model of Breast Cancer
Parvin Forghani ... Edmund K Waller
Blood | VOL. 124
Parvin Forghani, et. al.Parvin Forghani ... Edmund K Waller
06 Dec 2014
Elevated levels of circulating monocytic myeloid derived suppressor cells in splenectomised β-thalassaemia/HbE patients.
Kittiphong Paiboonsukwong ... Chayada Thiengtavor
British journal of haematology | VOL. 191
Kittiphong Paiboonsukwong, et. al.Kittiphong Paiboonsukwong ... Chayada Thiengtavor
05 Aug 2020
Abstract 1551: Targeting myeloid derived suppressor cells as novel strategy to enhance immunotherapy in murine prostate cancer models
Kiersten M Miles ... Li Shen
Cancer Research | VOL. 72
Kiersten M Miles, et. al.Kiersten M Miles ... Li Shen
15 Apr 2012
501 VISTA regulates the differentiation and suppressive function of myeloid-derived suppressor cells
Li Wang ... Keman Zhang
Journal for ImmunoTherapy of Cancer | VOL. 8
Li Wang, et. al.Li Wang ... Keman Zhang
01 Nov 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers